Key result
Nirsevimab reduces infant RSV hospitalizations by an estimated ~42% compared to standard practice.
Why the study?
Does nirsevimab reduce RSV-related medically attended lower respiratory tract disease in US infants compared to the pre-2023 standard of practice?
Does nirsevimab reduce RSV-related medically attended lower respiratory tract disease in US infants compared to the pre-2023 standard of practice?
Nirsevimab prophylaxis at observed and expanded coverage levels substantially reduces the public health burden of infant RSV, supporting efforts toward universal immunization.
Supports universal nirsevimab coverage in US infants; extends trial data with real-world evidence of population-level RSV burden reduction.
Nirsevimab has already achieved substantial reductions in RSV-associated clinical burden at current national coverage levels. Modeled increases in coverage demonstrate large, incremental public health gains with complete universal immunization yielding up to an 86% reduction in RSV MA-LRTDs. These findings highlight the importance of implementing strategies that enhance access, reduce inequities, and support higher, sustained coverage to maximize population-level benefits of RSV prophylaxis.
No takes yet. Share an insight, caveat, or question.
Yarnoff et al. (2026) studied Infants in the United States at risk of RSV medically attended lower respiratory tract disease during the 2024–2025 RSV season. Nirsevimab vs. Pre-2023 Standard of Practice with palivizumab only for high-risk infants (82% coverage) was evaluated on Medically attended RSV lower respiratory tract disease (MA-LRTD), including hospitalizations, emergency room visits, primary care visits, and RSV-related deaths (42% reduction in hospitalizations, 39% reduction in ER and primary care visits at 44.7% coverage; up to 86% reduction in MA-LRTDs at 100% coverage). Nirsevimab at 44.7% coverage averted 204,306 RSV medically attended lower respiratory tract diseases, including a 42% reduction in hospitalizations, projecting up to 86% reduction with universal coverage in US infants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: